Abstract：
:rAAVrh74.MCK.GALGT2 is a surrogate gene therapy that inhibits muscular dystrophy in multiple animal models. Here, we report on a dose-response study of functional muscle GALGT2 expression as well as toxicity and biodistribution studies after systemic intravenous (i.v.) delivery of rAAVrh74.MCK.GALGT2. A dose of 4.3 × 1014vg/kg (measured with linear DNA standard) resulted in GALGT2-induced glycosylation in the majority of skeletal myofibers throughout the body and in almost all cardiomyocytes, while several lower doses also showed significant muscle glycosylation. No adverse clinical signs or treatment-dependent changes in tissue or organ pathology were noted at 1 or 3 months post-treatment. Blood cell and serum enzyme chemistry measures in treated mice were all within the normal range except for alkaline phosphatase (ALP) activity, which was elevated in serum but not in tissues. Some anti-rAAVrh74 capsid T cell responses were noted at 4 weeks post-treatment, but all such responses were not present at 12 weeks. Using intramuscular delivery, GALGT2-induced muscle glycosylation was increased in Cmah-deficient mice, which have a humanized sialoglycome, relative to wild-type mice, suggesting that use of mice may underestimate GALGT2 activity in human muscle. These data demonstrate safety and high transduction of muscles throughout the body plan with i.v. delivery of rAAVrh74.MCK.GALGT2.
journal_name
Mol Ther Methods Clin Devjournal_title
Molecular therapy. Methods & clinical developmentauthors
Zygmunt DA,Xu R,Jia Y,Ashbrook A,Menke C,Shao G,Yoon JH,Hamilton S,Pisharath H,Bolon B,Martin PTdoi
10.1016/j.omtm.2019.10.005subject
Has Abstractpub_date
2019-10-21 00:00:00pages
305-319issn
2329-0501pii
S2329-0501(19)30113-5journal_volume
15pub_type
杂志文章abstract：:Identification and characterization of disease-associated variants in monogenic disorders is an important aspect of diagnosis, genetic counseling, prediction of disease severity, and development of therapy. However, the effects of disease-associated variants on pre-mRNA splicing and mRNA degradation are difficult to p...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.09.004
更新日期：2020-09-16 00:00:00
abstract：:Duchenne muscular dystrophy (DMD) is a fatal disease of striated muscle deterioration. A unique therapeutic approach for DMD is the use of synthetic membrane stabilizers to protect the fragile dystrophic sarcolemma against contraction-induced mechanical stress. Block copolymer-based membrane stabilizer poloxamer 188 (...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2015.42
更新日期：2015-11-11 00:00:00
abstract：:Recombinant adeno-associated virus (rAAV)rh74.MCK.GALGT2 is a muscle-specific gene therapy that is being developed to treat forms of muscular dystrophy. Here we report on an isolated limb infusion technique in a non-human primate model, where hindlimb blood flow is transiently isolated using balloon catheters to conce...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2018.06.002
更新日期：2018-07-14 00:00:00
abstract：:Adoptive natural killer (NK) cell therapy is attaining promising clinical outcomes in recent years, but improvements are needed. Genetic modification of NK cells with a tumor antigen-specific receptor on their surface coupled to intracellular signaling domains may lead to enhanced cytotoxicity against malignant cells....
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.03.017
更新日期：2020-03-29 00:00:00
abstract：:Exudative age-related macular degeneration (AMD), characterized by choroidal neovascularization (CNV), is the leading cause of irreversible blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs are the standard treatment for AMD, but they have limitations. Cell therapy is a promising a...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2019.05.007
更新日期：2019-05-22 00:00:00
abstract：:Possible risks and lack of donor livers limit application of liver transplantation. Liver cell transplantation is, at this moment, not a feasible alternative because engraftment in the liver is poor. Furthermore, there is also shortage of cells suitable for transplantation. Fetal liver cells are able to proliferate in...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2014.3
更新日期：2014-03-12 00:00:00
abstract：:Pompe disease is an autosomal recessive lysosomal storage disorder characterized by progressive muscle weakness. The disease is caused by mutations in the acid α-glucosidase (GAA) gene. Despite the currently available enzyme replacement therapy (ERT), roughly half of the infants with Pompe disease die before the age o...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.04.023
更新日期：2020-05-04 00:00:00
abstract：:Pancreatic cancer is an aggressive malignancy that often goes undiagnosed in the early stages. Non-invasive, early, and accurate diagnosis is therefore undoubtedly the "holy grail" of pancreatic cancer research. However, despite extensive research efforts, there is no definitive biomarker for this cancer. Previously, ...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2019.08.016
更新日期：2019-09-12 00:00:00
abstract：:Pompe disease (PD) is a lysosomal disorder caused by acid α-glucosidase (GAA) deficiency. Progressive muscular weakness is the major symptom of PD, and enzyme replacement therapy can improve the clinical outcome. However, to achieve a better clinical outcome, alternative therapeutic strategies are being investigated, ...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2016.54
更新日期：2016-08-10 00:00:00
abstract：:The His723Arg (H723R) mutation in SLC26A4, encoding pendrin, is the most prevalent mutation in East Asia, resulting in DFNB4, an autosomal recessive type of genetic hearing loss. Although the main pathological mechanism of H723R was identified as a protein-folding defect in pendrin, there is still no curative treatmen...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2019.11.019
更新日期：2019-11-30 00:00:00
abstract：:Vaccinia virus (VACV) was successfully used as a vaccine in the smallpox eradication campaign. Since then, it has been widely used in the development of vaccine and therapeutic vectors. However, methods of generating and purifying recombinant VACVs (rVACVs) are often time-consuming, cumbersome, and in some cases requi...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.03.026
更新日期：2020-03-30 00:00:00
abstract：:The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (Mycobacterium bovis bacillus Calmette-Guérin). With the aim of using MTBVAC as a v...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2019.01.014
更新日期：2019-02-07 00:00:00
abstract：:In vivo imaging of vector transgene expression would be particularly valuable for repetitive monitoring of therapy in the brain, where invasive tissue sampling is contraindicated. We evaluated adeno-associated virus vector expression of a dopamine-2 receptor (D2R) mutant (D2R80A) by positron emission tomography in the...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2014.16
更新日期：2014-06-04 00:00:00
abstract：:Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB [MPS IIIB]) is a lysosomal storage disorder primarily affecting the brain that is caused by a deficiency in the enzyme α-N-acetylglucosaminidase (NAGLU), leading to intralysosomal accumulation of heparan sulfate. There are currently no treatments for this dis...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2018.06.005
更新日期：2018-07-23 00:00:00
abstract：:New methods to produce large numbers of myeloid progenitor cells, precursors to macrophages (MΦs), by maintaining Hoxb8 transcription factor activity1 has reinvigorated interest in MΦ cell therapies. We generated Hoxb8-dependent myeloid progenitors (HDPs) by transducing lineage-negative bone marrow cells with a consti...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2017.08.007
更新日期：2017-09-07 00:00:00
abstract：:Hypophosphatasia (HPP) is an inherited disease caused by genetic mutations in the gene encoding tissue-nonspecific alkaline phosphatase (TNALP). This results in defects in bone and tooth mineralization. We recently demonstrated that TNALP-deficient (Akp2 (-/-) ) mice, which mimic the phenotype of the severe infantile ...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2015.59
更新日期：2016-02-03 00:00:00
abstract：:Herpes simplex keratitis (HSK) is the most common cause of corneal blindness in developed nations, caused by primary or recurrent herpes simplex virus 1 (HSV-1) infection of the cornea. Latent infection of HSV-1, especially in the trigeminal ganglion (TG), causes recurrence of HSV-1 infection. As antiviral treatment i...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.05.011
更新日期：2020-05-22 00:00:00
abstract：:The advent of RNA-guided endonuclease (RGEN)-mediated gene editing, specifically via CRISPR/Cas9, has spurred intensive efforts to improve the efficiency of both RGEN delivery and targeted mutagenesis. The major viral vectors in use for delivery of Cas9 and its associated guide RNA, lentiviral and adeno-associated vir...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2016.57
更新日期：2016-08-24 00:00:00
abstract：:Extracellular vesicles (EVs) are membranous structures that protect RNAs from damage when circulating in complex biological fluids, such as plasma. RNAs are extremely specific to health and disease, being powerful tools for diagnosis, treatment response monitoring, and development of new therapeutic strategies for sev...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.07.012
更新日期：2020-07-15 00:00:00
abstract：:Insertional mutagenesis has been associated with malignant cell transformation in gene therapy protocols, leading to discussions about vector security. Therefore, clonal analysis is important for the assessment of vector safety and its impact on patient health. Here, we report a unique approach to assess dynamic chang...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2014.52
更新日期：2014-11-19 00:00:00
abstract：:Endotoxin is the most common contaminant found in protein samples. Even a small amount of endotoxin can induce strong allergic reaction and death of a host organism. Endotoxin is also often detected in recombinant adeno-associated virus (rAAV) stocks prepared in research laboratories using off-the-shelf reagents; puri...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2019.08.013
更新日期：2019-09-06 00:00:00
abstract：:Gene therapy has been shown to be a feasible approach to treat inherited disorders in vivo. Among the currently used viral vector systems, adeno-associated virus (AAV) vectors are the most advanced and have been applied in patients successfully. An important drawback of non-integrating AAV vectors is their loss of exp...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2018.02.010
更新日期：2018-02-27 00:00:00
abstract：:Adeno-associated virus (AAV) vectors have become one of the most widely used gene transfer tools in human gene therapy. Considerable effort is currently being focused on AAV capsid engineering strategies with the aim of developing novel variants with enhanced tropism for specific human cell types, decreased human sero...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2018.10.016
更新日期：2018-11-01 00:00:00
abstract：:Lentiviral vectors have emerged as an efficient, safe therapeutic tool for gene therapy based on hematopoietic stem cells (HSCs) or T cells. However, the monitoring of transduced cells in preclinical models remains challenging because of the inefficient transduction of murine primary T cells with lentiviral vectors, i...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2018.08.002
更新日期：2018-08-08 00:00:00
abstract：:The delivery of factor VIII (FVIII) through gene and/or cellular platforms has emerged as a promising hemophilia A treatment. Herein, we investigated the suitability of human placental cells (PLCs) as delivery vehicles for FVIII and determined an optimal FVIII transgene to produce/secrete therapeutic FVIII levels from...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.03.001
更新日期：2020-03-14 00:00:00
abstract：:Retroviral vectors, including those derived from gammaretroviruses and lentiviruses, have found their way into the clinical arena and demonstrated remarkable efficacy for the treatment of immunodeficiencies, leukodystrophies, and globinopathies. Despite these successes, gene therapy unfortunately also has had to face ...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章,评审
doi：10.1016/j.omtm.2017.10.002
更新日期：2017-10-05 00:00:00
abstract：:Gene replacement therapies, like organ and cell transplantation are likely to introduce neo-antigens that elicit rejection via humoral and/or effector T cell immune responses. Nonetheless, thanks to an ever growing body of pre-clinical studies it is now well accepted that gene transfer protocols can be specifically de...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2014.13
更新日期：2014-04-30 00:00:00
abstract：:Recombinant adeno-associated viral (rAAV) vectors have been widely used in human gene therapy. One major impediment to its broad application is the inability to produce high-quality vectors in mass quantity. Here, an efficient and scalable suspension cell culture system for the production of rAAV vectors is described....
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2017.11.002
更新日期：2017-11-07 00:00:00
abstract：:Lentiviral vectors (LVs) are increasingly employed in gene and cell therapy. Standard laboratory production of LVs is not easily scalable, and research-grade LVs often contain contaminants that can interfere with downstream applications. Moreover, purified LV production pipelines have been developed mainly for costly,...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1016/j.omtm.2020.10.009
更新日期：2020-10-20 00:00:00
abstract：:Crigler-Najjar syndrome is a severe metabolic disease of the liver due to a reduced activity of the UDP Glucuronosyltransferase 1A1 (UGT1A1) enzyme. In an effort to translate to the clinic an adeno-associated virus vector mediated liver gene transfer approach to treat Crigler-Najjar syndrome, we developed and optimize...
journal_title：Molecular therapy. Methods & clinical development
pub_type： 杂志文章
doi：10.1038/mtm.2016.49
更新日期：2016-07-20 00:00:00
